Back to top

gene-editing: Archive

Zacks Equity Research

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

EDITNegative Net Change CTMXPositive Net Change SPROPositive Net Change CSTLNegative Net Change

Zacks Equity Research

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

ALNYNegative Net Change PFENegative Net Change GILDNegative Net Change QUREPositive Net Change

Zacks Equity Research

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

RHHBYNegative Net Change SRPTPositive Net Change ARWRPositive Net Change